REGENERON PHARMACEUTICALS, INC.
StreetZero Signal 60
About REGENERON PHARMACEUTICALS, INC.
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The company operates as a public B2B entity in the biotechnology sector with headquarters in Tarrytown, New York. It maintains a significant online presence with over 692,000 LinkedIn followers and has completed multiple funding rounds including grants and post-IPO equity.
LATEST FUNDINGRule 144
$958K
Announced 2026-11-17
TOTAL RAISED$719.15M
IN THE NEWS
- ๐ Regeneron
- ๐ Regeneron Pharmaceuticals - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- ๐ Regeneron Pharmaceuticals - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- ๐ How To Invest In Regeneron Pharmaceuticals Inc Stock - REGN Share Price Today & News | Stash
- ๐ Regeneron Pharmaceuticals, Inc. (REGN) Stock Price, News, Quote & History - Yahoo Finance
EMPLOYEES15410
FOUNDEDโ
HQTarrytown, New York, United States
Industry
Public Equity (NASDAQ)
Tags
BiotechnologyPublic CompanyB2BPharmaceuticals
Investors
Key highlights
- Completed Post-IPO Equity round of $2.03M in July 2024.
- Total historical funding reaches $719.15M including multiple grants.
- Publicly traded on NASDAQ under ticker REGN with market cap exceeding $95B.
- Employs 15,410 people and generates $16.9B in annual revenue.
Ask StreetZero about REGENERON PHARMACEUTICALS, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account